The Chief of Ghana’s 2014 Commonwealth Games team, Ben Nunoo Mensah is confident that the nation’s contingent will improve upon the four medals won at the Delhi 2010 Commonwealth Games by sweeping at least 12 medals at the Glasgow 2014 Games.“I believe that this Commonwealth Games will probably be the best that Ghana has ever participated in and trust me, we will come home with anything not less than 12 medals,” Mr. Nunoo Mensah said.The Sports Minister Hon. Elvis Afriyie Ankrah has stated that he is expecting the national sports teams to win more medals at this year’s Commonwealth Games compared to the three bronze and one silver medal Ghana won four years ago.With five months to the 2014 Commonwealth Games, which will be held from July 23 to August 3rd, there are plans for Ghana’s contingent to hold at least a one-month camping in Europe ahead of the multi-sport competition, according to Ben Nunoo Mensah.“I have just mentioned to the Committee that we are planning that Team Ghana could have at least a one-month camping in Europe before the Games start. So, if all these things go well, I should believe that by the 23rd of July Team Ghana should be ready for Games at least to give off our best,” he said.
Ghana striker Prince Tagoe is set to sign for Malaysian Super League side Kelantan, Africanfootball.com can exclusively reveal.The 27-year-old has been available on a free transfer after terminating his contract with Tunisian giants Club Africain.The former Hearts of Oak player will be signing for his ninth foreign club since leaving for Saudi Arabian side Al Ittihad in 2006.Kelantan president Annuar Musa on Tuesday uploaded a picture of him and the former TSG Hoffenheim player on his Facebook fan page.The Red Warriors are looking to replace their foreign players, after a string of disappointing results that culminated in their early exit from the 2014 AFC Cup on Tuesday night.Kelantan are fifth on the 12-team table with the second half of the season just underway. Tagoe has previously played for UAE’s Al Shabab, Saudi side Ettifaq, Partizan Belgrade and Turkish top-flight side Bursaspor.He played at the 2010 FIFA World Cup finals in South Africa and has made 36 appearances for the Ghana national team.
The Lakers should seriously consider adding Dwight Howard, according to multiple league executives.Los Angeles is reportedly interested in the 33-year-old center after DeMarcus Cousins tore his ACL during a workout last week. League executives told USA Today’s HoopsHype that inking Howard to a minimum deal is a low risk, high reward scenario. DeMarcus Cousins injury update: Lakers center tears ACL in Las Vegas workout Dwight Howard rumors: 3 reasons Lakers should pursue the big man Jrue Holiday discusses Pelicans trading Anthony Davis to Lakers, drafting Zion Williamson “I think it’s worth the risk for them,” one anonymous executive said. “If it doesn’t work out, they can cut bait.”Howard was sent from the Wizards to the Grizzlies in early July. Memphis is expected to waive Howard, which would make him a free agent, and the team has reportedly already given Los Angeles permission to speak with him. Related News Another executive told HoopsHype:“Personal baggage aside, I would sign him. He’s clearly the best player available if he’s healthy. We’ve heard the same song from him for years (as far as changing). But for the minimum? Why not? If it doesn’t work, they move on.”Howard was a star early in his career, however, he has struggled with injuries and reportedly clashed with teammates in recent seasons. He previously played for the Lakers in 2012-13 and said last month he was open to returning to Los Angeles.“It just wasn’t the right fit for me at the time,” Howard told the Los Angeles Times in early July. “But the Lakers have been doing something right for a long time because they have the most fans in the world and the most championships over the past 40 years. You’re not going to win a championship every year, but they’re back and will compete for a championship next season.”The Lakers rebuilt their roster this summer when they acquired Anthony Davis in a trade with the Pelicans to pair with LeBron James. They created cap space to add a third max player but missed out on Kawhi Leonard, who signed with the Clippers. Los Angeles then inked Avery Bradley, Danny Green, Kentavious Caldwell-Pope, JaVale McGee, Quinn Cook, Rajon Rondo and Alex Caruso to deals, in addition to Cousins.McGee is currently the only healthy center on the Lakers’ roster.
Join Andy Goldstein, Jason Cundy and chums as they round up the best bits from the Sports Bar week.
A vaccine against the disease leishmaniasis could save tens of thousands of lives every year. Now, scientists report that they have used snippets of DNA to spur mice to fight back against the parasites responsible for the illness, an approach they hope to soon begin testing in people.Leishmaniasis is caused by microscopic parasites of the genus Leishmania; some 20 different species can sicken humans. Leishmaniasis hits poor residents of tropical countries the hardest. The sandflies that spread the disease are silent and smaller than a mosquito. After a sandfly’s bite injects them into the body, Leishmania cells can attack the skin or mucous membranes, causing ulcers or disfiguring lesions. In an often lethal variety of the disease, they damage the liver, spleen, and bone marrow. Although the disease’s toll isn’t certain, estimates suggest there are about 1.3 million new cases and up to 40,000 deaths each year.Leishmania parasites are tricky foes, and so far no vaccine has received approval for use in humans. One challenge is that the parasites lay low inside our cells, out of reach of the antibodies triggered by most other vaccines. The key to eradicating these sheltered invaders, researchers suspect, is stimulating the immune cells known as T cells. Although two experimental leishmaniasis vaccines that use this strategy have undergone preliminary safety and effectiveness tests in people, the best method for enlisting T cells isn’t clear.Sign up for our daily newsletterGet more great content like this delivered right to you!Country *AfghanistanAland IslandsAlbaniaAlgeriaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBolivia, Plurinational State ofBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCongo, The Democratic Republic of theCook IslandsCosta RicaCote D’IvoireCroatiaCubaCuraçaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands (Malvinas)Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and Mcdonald IslandsHoly See (Vatican City State)HondurasHong KongHungaryIcelandIndiaIndonesiaIran, Islamic Republic ofIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People’s Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People’s Democratic RepublicLatviaLebanonLesothoLiberiaLibyan Arab JamahiriyaLiechtensteinLithuaniaLuxembourgMacaoMacedonia, The Former Yugoslav Republic ofMadagascarMalawiMalaysiaMaldivesMaliMaltaMartiniqueMauritaniaMauritiusMayotteMexicoMoldova, Republic ofMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorwayOmanPakistanPalestinianPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalQatarReunionRomaniaRussian FederationRWANDASaint Barthélemy Saint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint Martin (French part)Saint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint Maarten (Dutch part)SlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania, United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuela, Bolivarian Republic ofVietnamVirgin Islands, BritishWallis and FutunaWestern SaharaYemenZambiaZimbabweI also wish to receive emails from AAAS/Science and Science advertisers, including information on products, services and special offers which may include but are not limited to news, careers information & upcoming events.Required fields are included by an asterisk(*)Immunologist Peter Walden of Charité University Medicine Berlin and colleagues decided to try a DNA vaccine, a type of vaccine that is good at inciting T cells. Such vaccines contain DNA strands coding for proteins from a pathogen. Cells in the vaccine recipient’s body absorb the DNA and start churning out the proteins—also called antigens—which alert the immune system and prime it to attack if a real infection occurs.First, the researchers had to choose the right antigens. They settled on five different proteins that vary little across Leishmania samples from a range of species found around the world. To determine whether the antigens galvanize human T cells, the team obtained blood samples from people in India and Tunisia who had recovered from the disease or had been exposed to it without getting sick. They found that portions of all five proteins sparked a response by T cells from the blood samples.The researchers’ final vaccine mixture, which they tested in mice, contained five kinds of DNA strands, each coding for all or part of one of the proteins. The vaccine stimulated the mice to produce defenses against leishmaniasis parasites, Walden and colleagues report online today in Science Translational Medicine. T cells from the vaccinated animals reacted vigorously to Leishmania antigens. To confirm that the vaccine helped the animals combat the invaders, the researchers injected the mice with cells of one Leishmania species. Three weeks later, mice that received the highest vaccine dose carried 94% fewer parasites in their liver than did mice that received a control shot. Although some parasites remained in the mice that received the largest dose, Walden says there weren’t enough of them to cause disease symptoms.“We are ready for human trials,” he says. The vaccine should provide protection against different human Leishmania species, he adds, because the selected antigens are the same across species.Immunologist Paul Kaye of the University of York in the United Kingdom agrees that the time for human trials has come. “There is every reason to believe that they should move forward as soon as possible,” says Kaye, who’s excited that there are now three vaccines to try in humans. Kaye and colleagues’ own vaccine candidate, which stimulates T cells with a harmless virus that carries sections of two Leishmania genes, has already undergone a safety study in people, but the results have not yet been published.“This is a significant advance,” says vector biologist Jesus Valenzuela of the National Institute of Allergy and Infectious Diseases in Rockville, Maryland. Walden’s group deserves credit for using human blood samples to identify the antigens, he says; other vaccine developers have used rodents.Leishmaniasis is one of the neglected tropical diseases for which research cash is hard to obtain. Still, Walden is hopeful that he and his colleagues will find financing for safety trials.